- Dec 10, 2018 Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
- Nov 29, 2018 Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
- Nov 28, 2018 Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting
- Nov 09, 2018 Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Data provided by Nasdaq. Minimum 15 minutes delayed.